EUA Draft Guidance: FDA Wants ‘Transition Implementation Plan’ Along With Marketing Submission
Also: Makers of life-supporting, life-sustaining EUA devices should file “notification of intent” with agency
Executive Summary
In a long-awaited draft guidance document, the US agency lays bare its thinking on how companies can best ensure that their products granted emergency use authorization status can still be sold post-pandemic (or not).
You may also be interested in...
FDA Finalizes Guidance Documents Aimed At Easing Post-Pandemic Regulatory Transitions
The documents describe the US agency’s preferred approach toward products cleared under EUAs or other alternate approaches during the COVID-19 public health emergency.
FDA Reopens Pre-Submissions For Non-COVID-19 Products
The US agency now has the staff it needs to review pre-submissions for devices that aren’t related to the pandemic, says a new blog post from device center director Jeff Shuren and Office of Product Evaluation and Quality director William Maisel.
FDA Outlines Phased Approach To Return Products To Full Compliance After Emergency Use Ends
The US FDA says in a new draft guidance document that makers of a variety of devices and diagnostics that were given wide enforcement berth by the agency to use their products to respond to COVID-19 must eventually transition back to full regulatory compliance under a proposed three-phase plan.